| Today’s Big NewsMay 3, 2024 |
|
Therapeutic RNAs offer several advantages over other therapies due to their specificity and versatility, leading researchers to make great strides towards personalized medicine. Download the QPS white paper for insights into the future of RNA Therapies.
|
|
| By Gabrielle Masson Amgen is axing obesity candidate AMG 786 and going all in on later-stage asset MariTide. |
|
|
|
By Fraiser Kansteiner Shortly after Novo Holdings’ parent company elected to resubmit paperwork around the investment firm’s proposed $16.5 billion buyout of CDMO giant Catalent, the U.S. Federal Trade Commission has teed up a further extension on the deal’s review period. |
By Andrea Park Eli Lilly has a Fever, and the only prescription is a new corporate partnership. |
By Conor Hale QuidelOrtho has hunted for a new president and CEO since its board fired its last chief in February. Now it’s lured Brian Blaser out of retirement. |
|
Tuesday, May 14, 2024 | 9:30am ET / 6:30am PT This webinar dives into patient-derived organoids viewed as the gold standard in bridging the gap between the lab and the clinic. The oncology portfolio allows researchers to incorporate patient relevance at every stage of the drug development pipeline - from target discovery and hit identification to lead validation and optimization. Register now.
|
|
By Max Bayer CG Oncology’s late-stage bladder cancer treatment notched a complete response in roughly three-quarters of treated patients, fueling optimism that the company’s Wall Street success story is no fluke. |
By Angus Liu ImmunityBio last week won the FDA’s approval for its immunotherapy Anktiva to be used alongside the BCG vaccine to treat certain bladder cancers. Problem is, there is an ongoing global shortage of BCG, and ImmunityBio’s competitor, Merck & Co., is the sole supplier of BCG in the U.S. |
By Conor Hale The Fierce Medtech Fierce 15 winner secured another $100 million for its microbial DNA test that detects more than 1,000 different pathogens from a single blood sample. |
By James Waldron Medicxi co-founder Francesco De Rubertis pointed to the current popularity of secondary stock offerings as a sign that “investors are excited.” |
By Zoey Becker Leo Pharma's delgocitinib, which the company calls a potential growth driver, could shake up the topical JAK market and put pressure on Incyte's approved Opzelura. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we're diving into the details of the spree of big-money biopharma deals in 2023 and examining what that means for this year. |
|
|---|
|
|
|
Wednesday, May 22, 2024 | 11am ET / 8 am PT Learn GMP regulations in pharmaceutical storage at our upcoming webinar. Discover FDA requirements, including space validation, environmental controls, and risk mitigation. Explore services like aliquoting and cold chain transportation. Register now.
|
|
| WhitepaperThis paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion. Presented by: Blue Matter, strategic consultants in the life sciences |
| WhitepaperExplore the complex considerations of vaccine development for influenza and COVID-19, including the challenges posed by viral evolution and the importance of ongoing research in this paper by vaccine expert, Dr. Lisa Kierstead. Sponsored by: PPD®️ Laboratory Services |
| eBookTo make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
| WhitepaperDiscover the secrets behind successful patient engagement Sponsored by: ProofPilot |
| WhitepaperAntibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today! Sponsored by: Sengenics Corporation LLC |
| WhitepaperThe use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
| eBookUnlock the future of monoclonal antibody (mAb) manufacturing with a complete guide to enhancing productivity and quality for exceptional outcomes. Sponsored by: Thermo Fisher Scientific |
| WhitepaperThis paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperChoosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. Sponsored by: PPD®️ Laboratory Services |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
